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Abstract Gut microbiota is an essential component in the pathogenesis of liver cirrhosis and its 
complications. There is a direct relationship between the gut and the liver called the gut-
liver axis through which bacteria can reach the liver through the portal venous blood. 
However, it remains unclear how bacteria leave the intestine and reach the fluid 
collection in the abdomen. A series of mechanisms have been postulated to be involved 
in the pathogenesis of spontaneous bacterial peritonitis (SBP) and other complications of 
liver cirrhosis, including bacterial translocation, bacterial overgrowth, altered intestinal 
permeability and dysfunctional immunity. The hepatic function may also be affected by 
the alteration of intestinal microbiota composition. Current treatment in SBP is antibiotic 
therapy, but lately, probiotics have been the useful treatment suggested to improve the 
intestinal barrier and prevent bacterial translocation. However, studies are contradictory 
regarding their usefulness. In this review, we will summarize the literature data on the 
pathogenesis of spontaneous bacterial peritonitis concerning the existence of a 
relationship with the microbiota and the useful use of probiotics. 
Keywords  gut microbiota, bacterial translocation, spontaneous bacterial peritonitis, probiotics 
Highlights  Bacterial overgrowth is the consequence of delayed intestinal transit in patients with 
liver cirrhosis. 
 Probiotics are useful in treating and preventing hepatic encephalopathy, but this therapy 
seems to have an essential role in liver cirrhosis, non-alcoholic steatohepatitis and 
alcoholic liver disease. 
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Introduction 
Spontaneous bacterial peritonitis is the infection of the 
ascitic fluid by excluding possible surgical causes that can 
be treated. In 1970, the term was used by Harold Conn 
and Runyon to describe a large number of unexplained 
deaths before this infection was suspected in patients with 
an altered condition and ascites (1, 2). In patients with 
ascites, monitored throughout a year, spontaneous 
bacterial peritonitis (SBP) has had an incidence of 10-
30% and a hospital mortality rate of approximately 20% 
(3-5). The diagnosis of SBP is made due to the presence 
of more than 250/mm3 of polymorphonuclear leukocytes 
in the ascitic fluid and the isolation of a single germ from 
the bacteriological cultures (6-8). SBP is the most 
common type of infection in patients with hepatic 
cirrhosis, and 70-80% of cases have gram-negative 
bacteria such as E. coli and Klebsiella pneumonia as 
etiologic agents (9-11).  
The unfavorable evolution and prognosis of patients 
developing SBP suggest the idea of preventing the 
occurrence of this complication in cirrhotic patients. The 
current review aims to study the relationship between gut 
microbiota and pathogenic mechanisms involved in SBP, 
as well as the benefit of using probiotics to prevent SBP. 
We examined the literature data provided by 
MEDSCAPE and PubMed portals, and we chose the most 
reliable data provided by 38 studies and articles focusing 
on microbiota, probiotics, and SBP. We have eliminated 
those articles with uncertain statistics and with unclear 
design. 
Discussions 
Gut microbiota and pathogenic mechanism involved 
in spontaneous bacterial peritonitis  
With the help of the gut-liver axis, the intestine 
supplies blood to the portal system and activates the 
functions of the liver. Conversely, the liver produces bile 
and facilitates the intestinal function (12). Gut microbiota 
contains a considerable amount of microbes that exceed 
ten times the number of cells in the body, and many of 
them have not yet been identified (13). It also has many 
functions including bile acid degradation, vitamin 
synthesis and protection against pathogens with immunity 
(14, 15). Approximately 50% of patients with liver 
cirrhosis have experienced bacterial overgrowth 
compared to healthy people. By stimulating intestinal 
motility, one can reduce the number of bacteria (16). The 
key mechanism in SBP pathogenesis is bacterial 
translocation (BT). Usually, bacterial translocation is the 
passage of bacteria from the gut lumen into extra 
intestinal mesenteric lymph nodes (17). BT measurement 
can be performed indirectly by using surrogate parameters 
such as lipopolysaccharide (bacterial wall component), 
bacterial DNA or LPS binding protein (18). Usually, there 
is a smaller microbial density in the small intestine 
compared to the colon. However, there seems to be an 
increase in the bacteria count of the small intestine in 
patients with liver cirrhosis (19). An essential role in 
destroying the first defense mechanism of the mucosal 
barrier is nitric oxide. It triggers changes in the intestinal 
wall by enlarging the tight junctions in cultivated 
intestinal epithelial cells (20). There is also the 
destruction of the second defense mechanism represented 
by the expansion of the intercellular space between 
junctions (21). A recently discovered molecule critical in 
maintaining the intestinal barrier is the farnesoid X 
receptor (FXR) (22). The FXR synthetic antagonist can 
achieve BT cessation (23) and implicitly lower portal 
hypertension in animal models with cirrhosis (24), but 
experience in humans is still inexistent. Another factor 
contributing to the promotion of bactericidal translocation 
is deficient immunity, proved by an animal study that 
showed an increased intraepithelial lymphocyte with a 
low capacity to produce interferon and low proliferative 
activity (25). In conclusion, bacteremia and inoculation of 
ascitic fluid occur due to deficient immunity. The risk of 
developing SBP results from a low complement level in 
the ascitic fluid activity (26). Typically, local 
macrophages along with neutrophils contribute to the 
destruction of bacteria in the bloodstream. In cirrhotic 
patients, because of portal hypertension, circulating 
bacteria do not come in contact with Kupffer cells, and 
this leads to the occurrence of bacteremia. Thus, SBP is 
favored by neutrophil changes and low serum 
complement (27).   
Evidence regarding probiotic uses in the treatment of 
spontaneous bacterial peritonitis  
Because the most common causes of PBS include E. 
coli and Klebsiella, empirical therapy can use third-
generation cephalosporins, due to their broad spectrum of 
action and excellent safety profile. 
Cefotaxime is the most commonly used, but other 
agents such as ceftriaxone and ceftazidime have the same 
efficacy. Oral fluoroquinolones are an alternative for 
patients with good digestive tolerance (28). One study 
demonstrated that there are no significant differences in 
mortality rates, efficacy and adverse events following 
treatment with cephalosporins compared to other 
antibiotics. Although short and long-term treatments offer 
similar healing rates, the short-term treatment is 
Gut microbiota and spontaneous bacterial peritonitis 
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recommended (29, 30). Albumin treatment was effective 
in patients with serum bilirubin > 4 mg/dl, serum 
creatinine > 1 mg/dl and urea > 30 mg/dl. It is unclear 
whether they are beneficial in patients with low values of 
these parameters because the incidence of type 1 
hepatorenal syndrome was low in both groups (7% 
without albumin, 0% albumin) (31). Patients at high risk 
of developing PBS are patients with proteins from ascitic 
fluid <1g/dl (primary prevention), patients with active 
variceal bleeding and those with previous PBS (secondary 
prevention).   
A double-blind randomized placebo-controlled study 
on patients with severe hepatic disease and proteins from 
ascites <1.5g/dl and without previous episodes of PBS 
showed that norfloxacin 400 mg/day reduces the risk of 
PBS and improves the survival rate (32).  
An alternative to antibiotics in the treatment of SBP is 
the use of probiotics. These drugs have several effects, 
namely the ability to modulate intestinal flora and 
improve intestinal barrier function (33, 34). Data from the 
current literature are contradictory regarding the 
effectiveness of probiotics (35). The results do not 
support the idea that probiotics can be used to prevent 
PBS. In a study on rats with cirrhosis and ascites, they 
failed to prevent bacterial translocation and ascitic fluid 
infection (36). Chiva et al. conducted a study on 
laboratory rats with tetrachloromethane-induced liver 
cirrhosis. They tested the effects of probiotics such as 
Lactobacillus Johnsonii LA1 combined with antioxidants 
on the intestinal microbiota and bacterial translocation. 
The results showed that there was a decrease of BT in 
the treated rats compared to the untreated control group. 
However, the role of probiotics cannot be accurately 
attributed because antioxidant therapy alone has had the 
same effects (37). A similar study, but only with probiotic 
treatment, showed no significant effects on intestinal 
bacteria and bacterial translocation, suggesting that the 
beneficial effects in the anterior survey are the result of 
antioxidant therapy (38). Pande C et al. conducted a study 
on patients who had previously experienced a PBS 
episode or were at increased risk of developing this 
disease. They administered either norfloxacin with 
probiotics or placebo to norfloxacin and recorded the 
results for six months, including side effects and mortality 
rates. Thus, the addition of probiotics with norfloxacin 
has not been beneficial in terms of primary and secondary 
prophylaxis of PBS, nor in reducing the mortality rate 
(39). Instead, the beneficial effect of probiotics on hepatic 
encephalopathy was proved by a meta-analysis of 9 
studies (40). Moreover, Wong et al. surveyed patients 
diagnosed with NAFLD using Lepicol probiotic formula 
treatment and explained that probiotic treatment could 
improve fatty liver and AST (41). A study on patients 
with compensated alcoholic cirrhosis treated with 
Lactobacillus Casei Shirota showed that probiotics 
improve the phagocytic capacity of neutrophils (42).  
Conclusions 
Considering this close relationship between the 
microbiota and the liver, the role of the intestinal barrier 
seems to be the key in the pathogenesis of SBP. Bacterial 
translocation presents a complex pathogenic mechanism 
consisting in bacterial overgrowth, changes in the 
mucosal barrier and a weak local immune response. 
Bacterial overgrowth is the consequence of delayed 
intestinal transit in patients with liver cirrhosis. As for 
probiotics, there is evidence regarding their usefulness in 
treating and preventing hepatic encephalopathy. Also, this 
therapy proved its role in liver cirrhosis, non-alcoholic 
steatohepatitis and alcoholic liver disease. However, few 
recent studies have demonstrated that probiotic therapy 
has no benefits in the prevention of primary and 
secondary SBP. Therefore, more clinical trials are needed 
to establish their recommendation in SBP management.   
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